🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Extreme Weather Report, Oct 30, 2024. This is your weather on fossil fuels. Happy Halloween.

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients by Natalia Jiménez et al buff.ly/3TTC2Z7 #UroSoMe #MedTwitter #EUO #PCa #ProstateCancer

Our review on the current state of PARPi development for #prostatecancer is now out in European Urology Oncology - led by Francesca Zacchi + help from several experts in the field sciencedirect.com/science/articl…

🌟 Make your vote count! Support Raquel Perez-Lopez from VHIO in the myesr elections! 🗳️ "Bridging disciplines, empowering young talents, and driving innovation in imaging research to transform patient care across Europe."  🗓️ Cast your vote 👉 linke.to/ESR25RaquelPer…

Our latest paper is out in Cell Reports Medicine - Functional RAD51-IF to detect HRR defects in #ProstateCancer - exploring correlations between HRR mutations, HRD scores, and RAD51-IF in mPC biopsies #OpenAccess #CancerResearch cell.com/cell-reports-m…

Podcast especial en castellano! Guillermo de Velasco y yo discutimos con David Lorente el Uromigoscore para cáncer de próstata metastásico! Datos muy interesantes que reflejan la práctica clínica de más de 20 expertos de todo el mundo Uromigos Tres Uramigas Elena Castro

Ganadora de la I Beca FERO - Carmen Mateu para médicos investigadores Enhorabuena Dra. Raquel Perez-Lopez Perelada Vall d’Hebron Institute of Oncology (VHIO) #cancerdeprostata #vhio #becasFERO

📢#ASCO25 concomitant publication: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic HSPC: prevalence and impact on outcomes David Olmos David Lorente Ignacio González Ginel Nuria Romero C@silda Ll@cer Daniel Castellano Bernardo Herrera Imbroda tinyurl.com/yyd25nbc

📍So happy to be at #ASCO25 to present and discuss our model to guide complex treatment decisions in mCRPC ➡️We can optimize docetaxel timing after ARPi with a validated predictive tool David Olmos

🎉 Proud to present our SASAN-SPARING phase 2 trial poster today at #ASCO25! A novel bladder-sparing strategy using sasanlimab as maintenance after neoadjuvant chemo in MIBC. Integrating ctDNA, utDNA, and multi-omic biomarkers to personalize treatment and save bladders

Prof. Mary-Claire King has been named the 2025 Princess of Asturias Award laureate for science — amazing recognition. Her work on the BRCA1/2 genes led to transforming cancer care, including for men with #ProstateCancer fpa.es/en/princess-of… PCF Science CRIS contra el cáncer

Mary-Claire King to receive the Princesa de Asturias award in Spain for her work in genetics. She is known for identifying BRCA1 and BRCA2 and describing the Hereditary Breast and Ovarian Cancer Syndrome. This just one of her multiple contributions to science. ESMO - Eur. Oncology David Gillespie

David Olmos David Lorente

Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations. Read the opinion by Elena Castro in the #ESMODailyReporter 🔗 ow.ly/4kOC50WfVTQ #ProstateCancer #mHSPC #PersonalisedMedicine

Think you know what to expect at #EMUC25? The Steering Committee (Elena Castro, Arnulf Stenzl, & Alison Tree 💙) highlights topics you wouldn't want to miss. 👇 emuc.org/united-voices-… Want to submit your abstract or join as a delegate? Links are in the article. ESTRO ESMO - Eur. Oncology

🚨 New study published in Molecular Cancer Therapeutics ‼️ Led by Joaquin Mateo & Julian Brandariz and funded by Asociación Española Contra el Cáncer, it presents a novel one-two punch treatment with promising effects in preclinical models of advanced prostate cancer. ➡️ linke.to/MCTherapeutics…